CaroGen

Executive Summary

CaroGen Corporation is a privately held immunotherapy company leveraging its proprietary AVIDIO (Artificial Virus for Infectious Diseases & Immuno-Oncology) platform to develop novel RNA-based immunotherapies and vaccines. Founded in 2016 and headquartered in Farmington, Connecticut, the company focuses on oncology and infectious diseases. Its lead candidates target ovarian cancer and chronic hepatitis B, both areas of high unmet medical need. CaroGen's AVIDIO platform is designed to generate potent and durable immune responses by mimicking viral infection without causing disease, offering potential advantages over conventional vaccine and immunotherapy approaches. The company is currently in the Phase 1 stage of development, with initial clinical data expected to validate the platform's safety and immunogenicity. As a preclinical-to-early clinical stage biotech, CaroGen's near-term value hinges on successful Phase 1 readouts and its ability to attract partnerships or funding. The platform's versatility could support a broad pipeline, but the company has not disclosed detailed trial timelines or financial backing. While the technology holds promise, the lack of disclosed catalysts and early-stage risk warrant a moderate conviction. Success in upcoming trials would be pivotal for advancing toward Phase 2 and establishing proof-of-concept in humans.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim safety and immunogenicity data for ovarian cancer candidate35% success
• 2027Phase 1 initiation or interim data for chronic hepatitis B candidate30% success
• TBDPotential partnering or collaboration agreement20% success